Abstract
Despite long-standing and large-scale studies on the nature of cancer and the development of numerous antitumor drugs, the incidence of cancer is growing and the five-year survival rate of cancer patients diagnosed at the advanced stages of the disease remains unacceptably low. The author considers the causes of such failures, which lie in the very nature of malignant cells: they can adapt to and resist practically any systemic therapeutic intervention. In this context, considerable hopes are pinned on oncolytic viruses, which are medical agents of a new type, able to produce an integrated effect on the disease. In addition to their direct ability to kill tumor cells selectively, oncolytic viruses stimulate natural processes of immune surveillance and removal of cancer cells. Besides, oncolytic viruses can kill tumor-initiating cancer stem cells that are highly resistant to chemo- and radiotherapy, and overcome the immunosuppression of the tumor microenvironment. These features make oncolytic viruses unique anticancer agents that combat cancer cells by multiple natural mechanisms. To incorporate viral cancer therapy into mainstream medical practice, it is necessary to intensify basic research on viral oncolysis mechanisms, to develop new therapeutic viral strains and tests for their personalized selection, and to improve methods of the local and systemic delivery of oncolytic viruses to tumor locations. Trials of drugs that would accelerate the introduction of new viral strains into medical practice will also require cardinal changes. Achievements in this sphere will help to overcome many old problems in the therapy of metastatic forms of malignant diseases.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
P. Taylor, Global cancer therapeutics market: Emphasis on recurrent and metastatic divisions, BCC Research. Report Code: PHM177A (2017).
U. Ezer, Cancer immunology and oncolytic virology: Technologies and global markets, BCC Report, PHM129B (2017).
D. P. Lane, “Cancer. P53, guardian of the genome,” Nature 358, 15–16 (1992).
A. O. Zheltukhin and P. M. Chumakov, “Constitutive and induced functions of the p53 gene,” Biochemistry (Moscow) 13 (75), 1692–1721 (2010).
S. Dawood, L. Austin, and M. Cristofanilli, “Cancer stem cells: Implications for cancer therapy,” Oncology (Williston Park, New York) 28, 1101–1110 (2014).
L. Hui and Y. Chen, “Tumor microenvironment: Sanctuary of the devil,” Cancer Letts. 1 (368), 7–13 (2015).
S. Spranger and T. F. Gajewski, “Impact of oncogenic pathways on evasion of antitumor immune responses,” Nat. Rev. Cancer 18 (3), 139–147 (2018).
G. Romano and A. Gawlinski, “New frontiers in oncology: Immune checkpoint inhibitors in combination therapy,” Drugs Today (Barcelona, Spain) 53 (2), 103–115 (2017).
D. H. Yoon, M. J. Osborn, J. Tolar, and C. J. Kim, “Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): Combination or built-in CAR-T,” Int. J. Mol. Sci. 2 (19), 340–356 (2018).
G. Dock, “The influence of complicating diseases upon leukemia,” Am. J. Med. Sci. 127, 563–592 (1904).
E. Kelly and S. J. Russell, “History of oncolytic viruses: Genesis to genetic engineering,” Mol. Ther. 15, 651–659 (2007).
P. M. Chumakov, V. V. Morozova, I. V. Babkin, et al., “Oncolytic enteroviruses,” Mol. Biol. 5 (46), 639–650 (2012).
C. G. Lemay, B. A. Keller, R. E. Edge, et al., “Onco-lytic viruses: The best is yet to come,” Curr. Cancer Drug Targets 18, 109–123 (2018).
S. E. Lawler, M. C. Speranza, C. F. Cho, and E. A. Chiocca, “Oncolytic viruses in cancer treatment: A review,” JAMA Oncol. 3, 841–849 (2017).
L. K. Csatary and T. Bakács, “Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with highgrade glioblastoma,” JAMA 281, 1588–1589 (1999).
A. Desjardins, M. Gromeier, J. E. Herndon, et al., “Recurrent glioblastoma treated with recombinant poliovirus,” N. Engl. J. Med. 379, 150–161 (2018).
O. V. Matveeva, Z.-S. Guo, S. V. Shabalina, and P. M. Chumakov, “Oncolysis by paramyxoviruses: Multiple mechanisms contribute to therapeutic efficacy,” Mol. Ther. Oncolytics 2, 15011–15024 (2015).
H. F. Dvorak, “Leaky tumor vessels: Consequences for tumor stroma generation and for solid tumor therapy,” Prog. Clin. Biol. Res. 354A, 317–330 (1990).
L. A. Pikor, J. C. Bell, and J.-S. Diallo, “Oncolytic viruses: Exploiting cancer's deal with the devil,” Trends Cancer 1, 266–277 (2015).
C. J. Breitbach, B. D. Lichty, and J. C. Bell, “On colytic viruses: Therapeutics with an identity crisis,” EBio-Medicine 9, 31–36 (2016).
Y. Katayama, M. Tachibana, N. Kurisu, et al., “Onco-lytic reovirus inhibits immunosuppressive activity of myeloid-derived suppressor cells in a TLR3-dependent manner,” J. Immunol. 200, 2987–2999 (2018).
A. Samson, K. J. Scott, D. Taggart, et al., “Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade,” Sci. Transl. Med. 422 (10), eaam7577 (2018).
M. C. Bourgeois-Daigneault, D. G. Roy, A. S. Aitken, et al., “Neoadjuvant oncolytic virotherapy before surgery sensitizes triplenegative breast cancer to immune checkpoint therapy,” Sci. Transl. Med. 10 (422), eaao1641 (2018).
S. G. Warner, D. Haddad, J. Au, et al., “Oncolytic herpes simplex virus kills stem-like tumor-initiating colon cancer cells,” Mol. Ther. Oncolytics 3, 16013 (2016).
T. Demuth and M. E. Berens, “Molecular mechanisms of glioma cell migration and invasion,” J. Neurooncol. 70, 217–228 (2004).
Z. Zhu, M. J. Gorman, L. D. McKenzie, et al., “Zika virus has oncolytic activity against glioblastoma stem cells,” J. Exp. Med. 214, 2843–2857 (2017).
K. Twumasi-Boateng, J. L. Pettigrew, Y. Y. E. Kwok, et al., “Oncolytic viruses as engineering platforms for combination immunotherapy,” Nat. Rev. Cancer 18, 419–432 (2018).
G. Collet, C. Grillon, M. Nadim, and C. Kieda, “Trojan horse at cellular level for tumor gene therapies,” Gene 525, 208–216 (2013).
M. K. Voroshilova, “Virusological and immunological aspects of LEV application to oncological diseases,” in Beneceptor Nonpathogenic Strains of Enteroviruses: Preventive and Therapeutic Applications (Izd. Minzdrava SSSR, Moscow, 1988), pp. 24–29 [in Russian].
I. A. Tarasova, P. M. Chumakov, S. A. Moshkovskii, and M. V. Gorshkov, “Profiling modifications for glioblastoma proteome using ultra-tolerant database search: Are the peptide mass shifts biologically relevant or chemically induced?,” J. Proteomics 191, 16–21 (2018).
A. V. Lipatova, T. Kh. Le, A. O. Sosnovtseva, et al., “Cell receptors affect the susceptibility of tumor cells to enteroviruses,” Byull. Eksp. Biol. Med. 7 (166), 66–70 (2018).
Author information
Authors and Affiliations
Corresponding author
Additional information
Petr Mikhailovich Chumakov, Dr. Sci. (Biol.), is Head of the Cell Proliferation Laboratory of the Engelhardt Institute of Molecular Biology, RAS, ’and Head of the Department of Innovative Immunobiology and Biotechnology Products of the Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products, RAS.
Russian Text © The Author(s), 2019, published in Vestnik Rossiiskoi Akademii Nauk, 2019, Vol. 89, No. 5, pp. 475–484.
Rights and permissions
About this article
Cite this article
Chumakov, P.M. Could Oncolytic Viruses Provide a Breakthrough in Oncology?. Her. Russ. Acad. Sci. 89, 171–178 (2019). https://doi.org/10.1134/S1019331619020023
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1019331619020023